Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilatedview more Reverse remodelling by sacubitril/valsartan predicts the prognosis in HFrEF fraction view more The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysisview more Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril–valsartan in Heart Failure with Reduced Ejectioview more Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal diseaseview more Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from theview more ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fractionview more Eligibility and Usage of Sacubitril/Valsartan in Koreaview more Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitationview more
